TY - JOUR
T1 - Success Predictors of Endoscopic Sleeve Gastroplasty
AU - Matteo, M. V.
AU - Bove, V.
AU - Ciasca, Gabriele
AU - Carlino, G.
AU - Di, Santo R.
AU - Vinti, L.
AU - Polidori, G.
AU - Pontecorvi, V.
AU - Papi, Massimiliano
AU - Spada, Cristiano
AU - Boskoski, Ivo
PY - 2024
Y1 - 2024
N2 - Objective Endoscopic sleeve gastroplasty (ESG) is a minimally invasive procedure that proved to be safe and effective in obesity treatment. However, not all subjects respond to treatment in the same way, and, with a view to personalized care, it is essential to identify predictors of success or failure. Methods A retrospective 2-year followed-up cohort of ESG subjects was analyzed to investigate the presence of any baseline or early indicators of long-term optimal or suboptimal ESG outcomes. Results A total of 315 subjects (73% women) were included, with 73% of patients exhibiting an Excess weight loss percentage (%EWL) >25% at the 24 months. Neither demographic parameters (age and sex), smoking habits, and menopause in women nor the presence of comorbidities proved potential predictive value. Interestingly, the %EWL at 1 month after ESG was the strongest predictor of 24-month therapeutic success. Subsequently, we estimated an "early threshold for success" for 1 month-%EWL by employing Youden's index method. Conclusions ESG is a safe and effective bariatric treatment that can be offered to a wide range of subjects. Early weight loss seems to impact long-term ESG results significantly and may allow proper early post-operative care optimization.
AB - Objective Endoscopic sleeve gastroplasty (ESG) is a minimally invasive procedure that proved to be safe and effective in obesity treatment. However, not all subjects respond to treatment in the same way, and, with a view to personalized care, it is essential to identify predictors of success or failure. Methods A retrospective 2-year followed-up cohort of ESG subjects was analyzed to investigate the presence of any baseline or early indicators of long-term optimal or suboptimal ESG outcomes. Results A total of 315 subjects (73% women) were included, with 73% of patients exhibiting an Excess weight loss percentage (%EWL) >25% at the 24 months. Neither demographic parameters (age and sex), smoking habits, and menopause in women nor the presence of comorbidities proved potential predictive value. Interestingly, the %EWL at 1 month after ESG was the strongest predictor of 24-month therapeutic success. Subsequently, we estimated an "early threshold for success" for 1 month-%EWL by employing Youden's index method. Conclusions ESG is a safe and effective bariatric treatment that can be offered to a wide range of subjects. Early weight loss seems to impact long-term ESG results significantly and may allow proper early post-operative care optimization.
KW - ESG
KW - Endoscopic sleeve gastroplasty
KW - Obesity
KW - Predictors
KW - ESG
KW - Endoscopic sleeve gastroplasty
KW - Obesity
KW - Predictors
UR - https://publicatt.unicatt.it/handle/10807/297365
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85186935282&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85186935282&origin=inward
U2 - 10.1007/s11695-024-07109-4
DO - 10.1007/s11695-024-07109-4
M3 - Article
SN - 0960-8923
VL - 34
SP - 1496
EP - 1504
JO - Obesity Surgery
JF - Obesity Surgery
IS - 5
ER -